CryoPort (NASDAQ:CYRX) Director Ramkumar Mandalam Sells 11,570 Shares of Stock

CryoPort, Inc. (NASDAQ:CYRX) Director Ramkumar Mandalam sold 11,570 shares of the company’s stock in a transaction dated Wednesday, December 10th. The shares were sold at an average price of $9.99, for a total value of $115,584.30. Following the sale, the director owned 80,758 shares in the company, valued at approximately $806,772.42. The trade was a 12.53% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

CryoPort Trading Down 2.5%

Shares of CYRX stock opened at $9.40 on Friday. CryoPort, Inc. has a fifty-two week low of $4.58 and a fifty-two week high of $11.44. The company has a debt-to-equity ratio of 0.40, a quick ratio of 15.01 and a current ratio of 15.77. The stock has a 50 day simple moving average of $9.43 and a two-hundred day simple moving average of $8.48. The company has a market cap of $470.66 million, a P/E ratio of 8.03 and a beta of 1.51.

CryoPort (NASDAQ:CYRX) last announced its quarterly earnings data on Tuesday, November 4th. The company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.05. The company had revenue of $44.23 million during the quarter, compared to the consensus estimate of $41.22 million. CryoPort had a net margin of 35.57% and a negative return on equity of 11.07%. Research analysts forecast that CryoPort, Inc. will post -0.99 earnings per share for the current year.

Institutional Investors Weigh In On CryoPort

Institutional investors have recently bought and sold shares of the stock. The Manufacturers Life Insurance Company lifted its stake in CryoPort by 9.4% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,178 shares of the company’s stock valued at $136,000 after acquiring an additional 1,557 shares in the last quarter. Avanza Fonder AB raised its holdings in shares of CryoPort by 31.4% in the second quarter. Avanza Fonder AB now owns 10,882 shares of the company’s stock valued at $81,000 after purchasing an additional 2,601 shares during the last quarter. Nisa Investment Advisors LLC lifted its position in shares of CryoPort by 299.9% during the second quarter. Nisa Investment Advisors LLC now owns 3,639 shares of the company’s stock valued at $27,000 after purchasing an additional 2,729 shares in the last quarter. MetLife Investment Management LLC boosted its holdings in CryoPort by 13.8% during the first quarter. MetLife Investment Management LLC now owns 24,641 shares of the company’s stock worth $150,000 after purchasing an additional 2,980 shares during the last quarter. Finally, State of Wyoming boosted its holdings in CryoPort by 30.2% during the second quarter. State of Wyoming now owns 14,218 shares of the company’s stock worth $106,000 after purchasing an additional 3,301 shares during the last quarter. Institutional investors own 92.90% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have weighed in on the stock. Needham & Company LLC lifted their price target on shares of CryoPort from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Wednesday, November 5th. UBS Group raised their target price on CryoPort from $11.00 to $12.50 and gave the company a “buy” rating in a research note on Wednesday, November 5th. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of CryoPort in a research note on Monday. Finally, BTIG Research increased their price target on CryoPort from $10.00 to $15.00 and gave the stock a “buy” rating in a report on Thursday, September 18th. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $12.83.

CryoPort Company Profile

Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.